CY1109773T1 - Φαρμακα για ασθενειες των αρθρωσεων - Google Patents

Φαρμακα για ασθενειες των αρθρωσεων

Info

Publication number
CY1109773T1
CY1109773T1 CY20101100507T CY101100507T CY1109773T1 CY 1109773 T1 CY1109773 T1 CY 1109773T1 CY 20101100507 T CY20101100507 T CY 20101100507T CY 101100507 T CY101100507 T CY 101100507T CY 1109773 T1 CY1109773 T1 CY 1109773T1
Authority
CY
Cyprus
Prior art keywords
diseases
zinc
medications
joints
hyaluronic acid
Prior art date
Application number
CY20101100507T
Other languages
English (en)
Inventor
Isao Serizawa
Keisei Maekawa
Janos Illes
Erzsebet Neszmeli
Original Assignee
Takata Seiyaku Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takata Seiyaku Co., Ltd filed Critical Takata Seiyaku Co., Ltd
Publication of CY1109773T1 publication Critical patent/CY1109773T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Φάρμακα για ασθένειες των αρθρώσεων όπως η ρευματοειδής αρθρίτιδα τα οποία περιέχουν ως ενεργό συστατικό ένα σύμπλοκο (συνδυασμός) υαλουρονικού οξέος με ψευδάργυρο. Σε σύγκριση με το υαλουρονικό οξύ και τον ψευδάργυρο (δηλαδή τα συστατικά αυτού), το σύμπλοκο αυτό αναστέλλει συνεργιστικά τον πολλαπλασιασμό των αρθρικών κυττάρων και συνεπώς ρυθμίζει την παραγωγή του ιστοκλαστικού ενζύμου ΜΜΡ-9 που παράγεται από αρθρικά κύτταρα.
CY20101100507T 1999-03-10 2010-06-08 Φαρμακα για ασθενειες των αρθρωσεων CY1109773T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP06371899A JP2003089647A (ja) 1999-03-10 1999-03-10 関節性疾患治療剤
EP00908017A EP1166788B8 (en) 1999-03-10 2000-03-10 Remedies for joint diseases

Publications (1)

Publication Number Publication Date
CY1109773T1 true CY1109773T1 (el) 2014-09-10

Family

ID=13237463

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100507T CY1109773T1 (el) 1999-03-10 2010-06-08 Φαρμακα για ασθενειες των αρθρωσεων

Country Status (21)

Country Link
US (1) US6608043B1 (el)
EP (1) EP1166788B8 (el)
JP (1) JP2003089647A (el)
KR (1) KR100728096B1 (el)
CN (1) CN1165315C (el)
AT (1) ATE466584T1 (el)
AU (1) AU2942500A (el)
BG (1) BG65681B1 (el)
CA (1) CA2364451C (el)
CY (1) CY1109773T1 (el)
CZ (1) CZ301736B6 (el)
DE (1) DE60044341D1 (el)
DK (1) DK1166788T3 (el)
EA (1) EA005010B1 (el)
EE (1) EE04660B1 (el)
ES (1) ES2344677T3 (el)
PL (1) PL200848B1 (el)
PT (1) PT1166788E (el)
SK (1) SK287223B6 (el)
UA (1) UA72913C2 (el)
WO (1) WO2000053194A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
ITRM20030590A1 (it) * 2003-12-22 2005-06-23 Univ Siena Formulazione a base di polimetafosfati per la cura di artropatie microcristalline.
WO2005089800A1 (ja) * 2004-03-17 2005-09-29 Locomogene, Inc. hsHRD3を含む医薬組成物
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
CA2560844C (en) * 2005-09-26 2011-05-17 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
JP2009091248A (ja) * 2006-01-17 2009-04-30 Toshitsu Kagaku Kenkyusho:Kk 外傷性神経障害および／または運動機能障害の治療薬
BRPI0621470A2 (pt) 2006-12-05 2011-12-13 Glycoscience Lab Inc agente terapêutico para artrite degenerativa
FR2927255B1 (fr) * 2008-02-07 2011-08-12 Keysan Consulting Produits injectables biocompatibles a liberation de zinc et/ou de sel de saccharide sous forme de zinc et leurs utilisations.
US8462765B2 (en) * 2008-08-20 2013-06-11 Qualcomm Incorporated Method and apparatus to perform ranging operations for wireless stations
JP5587637B2 (ja) * 2009-04-10 2014-09-10 生化学工業株式会社 マトリックスメタロプロテアーゼ阻害剤及びその用途
HUP0900717A3 (en) 2009-11-18 2012-02-28 Richter Gedeon Nyrt Pharmaceutical composition for urological use containing zinc hyaluronate
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
ES2665254T3 (es) * 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746504A (en) * 1986-03-14 1988-05-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
CA1291123C (en) 1986-03-14 1991-10-22 Abraham Nimrod Heavy metal salts of hyaluronic acid useful as antimicrobial agents
CA1327354C (en) * 1987-03-19 1994-03-01 David Cullis-Hill Anti-inflamatory compounds and compositions
AU616502B2 (en) * 1988-04-22 1991-10-31 Medvet Science Pty. Ltd. Treatment of inflammatory disorders in humans
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
CZ202591A3 (cs) * 1991-07-02 1993-01-13 Hypro Vyzkum Prostředek pro prevenci dekubitft a topickou terapii kožních lézt
US5744442A (en) * 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
IT1281877B1 (it) * 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici
IT1288290B1 (it) 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
EP0834319A1 (en) * 1996-10-07 1998-04-08 Kartar Dr. Lalvani Mineral and vitamin combinations in arthritic pain

Also Published As

Publication number Publication date
PL200848B1 (pl) 2009-02-27
SK12502001A3 (sk) 2002-02-05
EP1166788B8 (en) 2010-06-16
CA2364451A1 (en) 2000-09-14
UA72913C2 (en) 2005-05-16
DK1166788T3 (da) 2010-08-23
SK287223B6 (sk) 2010-03-08
WO2000053194A1 (fr) 2000-09-14
DE60044341D1 (de) 2010-06-17
PL350289A1 (en) 2002-12-02
EE200100478A (et) 2003-02-17
EP1166788A4 (en) 2007-10-10
ES2344677T3 (es) 2010-09-03
CN1343122A (zh) 2002-04-03
BG105885A (en) 2002-06-28
KR20010108343A (ko) 2001-12-07
EA200100963A1 (ru) 2002-02-28
BG65681B1 (bg) 2009-06-30
EP1166788B1 (en) 2010-05-05
PT1166788E (pt) 2010-06-25
EP1166788A1 (en) 2002-01-02
CA2364451C (en) 2011-08-02
CZ20013110A3 (cs) 2002-01-16
CN1165315C (zh) 2004-09-08
CZ301736B6 (cs) 2010-06-09
KR100728096B1 (ko) 2007-06-14
ATE466584T1 (de) 2010-05-15
EE04660B1 (et) 2006-08-15
AU2942500A (en) 2000-09-28
JP2003089647A (ja) 2003-03-28
EA005010B1 (ru) 2004-10-28
US6608043B1 (en) 2003-08-19

Similar Documents

Publication Publication Date Title
CY1109773T1 (el) Φαρμακα για ασθενειες των αρθρωσεων
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
EA200500488A1 (ru) Фармацевтические составы модафинила
IL172773A0 (en) Formulations for the treatment of arhritis conditions
BR0313059A (pt) Método para tratar ou prevenir uma doença auto-imune e/ou um ou mais sintomas associados com a mesma
ATE425253T1 (de) Tribonektine
ATE514418T1 (de) Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
BR0308613A (pt) Combinação de compostos orgânicos
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
MX2007008227A (es) Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.
GB0222514D0 (en) Organic compounds
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
GEP20084490B (en) Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
EP1238669A3 (en) Neutrophil function inhibitors which contain glucosamine
NO20031650D0 (no) Nye legemidler for leversykdommer
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS
BR0116263A (pt) Derivados de diidroindol e tetraidroquinolina
EP1563836A4 (en) ACTIVE SUBSTANCE FOR INHIBITING MATRIX METALOPROTEASE-9 PRODUCTION